SCI reúne recursos sobre inmunidad y SARS-CoV-2

84. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview . Diabetes Metab Syndr. 2020 Apr 18; doi: 10.1016/j.dsx.2020.04.020.
84. Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection. J Allergy Clin Immunol Pract. 2020 Apr 18; doi: 10.1016/j.jaip.2020.04.014.
83. FAMA Therapeutic and prophylactic potential of anti-microbial peptides against coronaviruses. Ir J Med Sci. 2020 Apr 18:1–2; doi: 10.1007/s11845-020-02232-4.
82. The Promise and Peril of Antibody Testing for COVID-19. JAMA, 2020; doi:10.1001/jama.2020.6170.
81. Immune Thrombocytopenic Purpura in a Patient with Covid-19. N Eng J Med 2020; DOI: 10.1056/NEJMc2010472.
80. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. J Infect. 2020 Apr 18; doi: 10.1016/j.jinf.2020.04.012.
79. Precision medicine in COVID-19: IL-1ß a potential target. JACC Basic Transl Sci. 2020 Apr 18; doi: 10.1016/j.jacbts.2020.04.006.
78. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. Mult Scler Relat Disord. 2020 Apr 18:102135; doi: 10.1016/j.msard.2020.102135.
77. Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med. 2020;18:165.
76. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18:164.
75. COVID-19 and Bacillus Calmette-Guérin: What is the Link? Eur Urol Oncol. 2020 Apr 13; doi: 10.1016/j.euo.2020.04.001.
74. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020 Apr 13; doi: 10.1016/j.bbi.2020.04.027.
73. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020 Apr 13:106504; doi: 10.1016/j.intimp.2020.106504.
72. Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate. Int Immunopharmacol. 2020 Jul;84:106495.
71. The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol. 2020 Apr 12:104361; doi: 10.1016/j.jcv.2020.104361.
70. Can an effective SARS-CoV-2 vaccine be developed for the older population? Immun Ageing. 2020;17:8.
69. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance. Comput Biol Med. 2020 Apr 11:103749; doi: 10.1016/j.compbiomed.2020.103749.
68. Persistence of memory in times of COVID-19. Trends Immunol. 2020 Apr 11; doi: 10.1016/j.it.2020.04.002.
67. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 2020; DOI: https://doi.org/10.1016/S0140-6736(20)30628-0.
66. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020; https://doi.org/10.1038/s41423-020-0402-2.
65. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases, 2020:ciaa248; https://doi.org/10.1093/cid/ciaa248.
64. A serological assay to detect SARS-CoV-2 seroconversion in humans. MedXriv, 2020; doi: https://doi.org/10.1101/2020.03.17.20037713.
63. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical Infectious Diseases, 2020:ciaa310; https://doi.org/10.1093/cid/ciaa310.
62. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020; https://doi.org/10.1002/jmv.25727.
61. Developing antibody tests for SARS-CoV-2. World Report 2020;395(10230):1101-1102.
60. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science 2020:eabb7269. DOI: 10.1126/science.abb7269.
59. Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. Am J Clin Dermatol. 2020 Apr 10:1–5; doi: 10.1007/s40257-020-00514-2.
58. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. GeroScience. 2020 Apr 10:1–10; doi: 10.1007/s11357-020-00186-0.
57. Challenges of Convalescent Plasma Therapy on COVID-19. J Clin Virol. 2020 Apr 10:104358; doi: 10.1016/j.jcv.2020.104358.
56. Pathogenic Priming Likely Contributes to Serious and Critical Illness and Mortality in COVID-19 via Autoimmunity. Journal of Translational Autoimmunity 2020;3:100051.
55. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020 Apr 9:1–2; doi: 10.1038/s41577-020-0308-3.
54. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. PNAS, 2020;117(14):8094-8103.

53. COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster. Clin Immunol. 2020 Apr 8:108413; doi: 10.1016/j.clim.2020.108413.
52. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol. 2020 Apr 8:108410; doi: 10.1016/j.clim.2020.108410.
51. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020 Apr 7:104791. doi: 10.1016/j.antiviral.2020.104791.
50. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfusion Medicine Reviews, 2020; https://doi.org/10.1016/j.tmrv.2020.02.0030887-7963.